Ingredient in Wegovy and Ozempic Raises Gut Health Concerns

Scientists are investigating the potential effects of salcaprozate sodium (SNAC), an ingredient used in oral formulations of weight loss drugs like Wegovy and Ozempic, on gut health and overall metabolic function. While SNAC is crucial for enabling the oral delivery of semaglutide, recent research suggests it may have broader biological impacts beyond simply aiding drug absorption.

The Role of SNAC in Oral Semaglutide

Semaglutide, the active ingredient in Wegovy and Ozempic, is typically administered via injection. However, when taken in pill form, semaglutide requires SNAC to protect it from breakdown in the stomach and facilitate its absorption into the bloodstream. Oral semaglutide is ineffective without SNAC.

Animal Study Reveals Potential Gut Microbiome Disruptions

A recent study conducted by researchers at Adelaide University examined the effects of SNAC on gut microbiota, metabolic function, and related health markers in rats. The findings, published in the Journal of Controlled Release, revealed several notable changes:

• A decrease in beneficial gut bacteria responsible for breaking down dietary fiber, specifically Muribaculaceae (-62%) and Bacteroidaceae (-77%).
• Lower levels of short-chain fatty acids (SCFAs), which are vital for gut health and inflammation control. Fecal butyrate concentrations were reduced by 77% with SNAC and 75% with the combination of SEM-SNAC.
• Increased levels of inflammatory markers in the blood, such as tumor necrosis factor-α (TNF-α), which increased by 70%.
• Increased liver weight, potentially indicating low-grade inflammation.
• A smaller cecum, the part of the intestine where gut bacteria break down fiber.
• Reduced levels of brain-derived neurotrophic factor (BDNF), a protein associated with cognitive function, which was suppressed by 85%.

Inflammation and Systemic Effects

The study too indicated a link between SNAC exposure and systemic inflammation. Researchers observed elevated levels of TNF-α, suggesting a potential inflammatory response. These changes in inflammatory markers correlated with alterations in the gut microbiome.

Global Obesity Trends and Increasing SNAC Exposure

Obesity is a significant global health concern, affecting approximately 890 million adults and 160 million children worldwide – roughly one in eight people. The United States has the highest prevalence of obesity among OECD countries (43% of the population aged 15 and over), while Australia ranks sixth (31%). With the increasing apply of oral semaglutide, exposure to SNAC is expected to rise significantly.

Need for Further Research

Researchers emphasize that these findings are from animal studies and do not definitively prove harm to humans. However, they highlight the importance of understanding the broader biological effects of SNAC and other absorption enhancers used in oral medications. Lead author Amin Ariaee, a PhD candidate at Adelaide University, stated the need to fully understand how each ingredient in these drugs affects the body over time. Further investigation is crucial to assess the long-term effects of chronic SNAC exposure.

Key Takeaways

• SNAC, used to enhance the oral absorption of semaglutide, may alter gut microbiota composition.
• Changes in gut bacteria are associated with reduced SCFA production and increased inflammation.
• Further research is needed to determine the long-term effects of SNAC exposure in humans.
• The increasing use of oral semaglutide necessitates a comprehensive understanding of all drug components, not just the active ingredient.